NEWS
AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes
AngioDynamics, Inc. (NASDAQ: ANGO) has launched the RECOVER-AV clinical trial to evaluate the AlphaVac F18⁸⁵ System for treating acute, intermediate-risk pulmonary embolism (PE) in the European market.
This multi-center, multi-national study follows the successful APEX-AV trial in the US, which showed significant improvements in right ventricular function and clot burden reduction
.
The RECOVER-AV trial will enroll patients across up to 20 European hospital sites, focusing on the reduction of the right ventricular/left ventricular ratio and major adverse events. Patients will be followed for 12 months to assess functional outcomes. This study is significant given the higher prevalence and acuity of PE in Europe compared to the US.
The RECOVER-AV trial will enroll patients across up to 20 European hospital sites, focusing on the reduction of the right ventricular/left ventricular ratio and major adverse events. Patients will be followed for 12 months to assess functional outcomes. This study is significant given the higher prevalence and acuity of PE in Europe compared to the US.
The AlphaVac F18⁸⁵ System recently received CE Mark approval in Europe for non-surgical removal of thrombi or emboli from pulmonary arteries. The trial is led by renowned experts in vascular medicine and cardiology, supported by an international Scientific Advisory Board.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2310Followers
105Following
24KVisitors
Follow